Charles Explorer logo
🇬🇧

Implementation studies in rare tumors is possibility

Publication at First Faculty of Medicine |
2009

Abstract

Conference Gastrointestinal Cancers in San Francisco have presented two studies - PROMID and RADIANT-1, which evaluated the effect therapy of somatostatin analogue and everolim. Studies in the treatment of neuroendocrine tumors fail.